Cipher Pharmaceuticals Inc (TSE:CPH) has released an update.
Cipher Pharmaceuticals Inc. saw a robust first quarter in 2024, with a notable 20% increase in total revenue to $5.9 million and a 12.5% rise in adjusted EBITDA, reaching $3.6 million. The company’s cash reserves are strong at $42 million, with no debt, and growth is anticipated through new product launches, such as MOB-015, and strategic North American acquisitions. The Canadian product Epuris continues to excel, maintaining a 45% market share as the leading isotretinoin in the country.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
